(d) Effective January 23, 2013, the board of directors (the "Board") of OXiGENE, Inc. (the "Company") increased the size of the Board by one, from five (5) to six (6) members, and approved the election of Dr. David (Dai) Chaplin to fill the newly created directorship, effective immediately. Dr. Chaplin has not been appointed to any committee of the Board and his election to the Board was not due to any arrangement or understanding with any other person.

Dr. Chaplin and the Company have entered into a consulting agreement pursuant to which Dr. Chaplin will be paid $5,000 per month to consult with the Company regarding alliance management and technical support of OXiGENE and Baylor University's ongoing sponsored research programs. A copy of the Consulting Agreement is attached hereto as Exhibit 10.1 and incorporated herein by reference.

In addition, as a non-employee member of the Board, Dr. Chaplin will be compensated for his service on the Board in accordance with the Company's Amended and Restated Non-Employee Director Compensation Policy, adopted by the Company on September 20, 2011, as described under the heading "Director Compensation" in the Definitive Proxy Statement filed by the Company with the Commission on April 20, 2012, and which is filed as Exhibit 10.34 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2011 and incorporated herein by reference.

(d) Exhibits

          Exhibit Number   Description

          10.1             Form of Consulting Agreement with Dr. Chaplin

          99.1             Press Release dated January 23, 2013